Thermo Fisher will expand use of the Sanofi site to meet the demand from pharma and biotech customers for U.S. manufacturing capacity.

The transaction between Thermo Fisher and Sanofi is scheduled for completion in Q2 2025, subject to standard closing ...

With an aim to enable additional U.S. drug product manufacturing, Thermo Fisher Scientific and Sanofi have decided to expand their strategic partnership. Under the terms of the agreement, Thermo ...

Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support ...

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

In a move to bolster its drug manufacturing capabilities in the United States, Thermo Fisher has purchased a sterile fill-finish and packaging plant from Sanofi in Ridgefield, New Jersey.

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

Teva Pharmaceutical Industries Limited’s TEVA shares have risen 21.6% in three months. Over the past few quarters, Teva has ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced that the US FDA approved Dupixent® (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP).